**Specifications Table**TableSubject area*Biology*More specific subject area*Acute cardiac care*Type of data*Tables*How data was acquired*Data analysis for national health insurance database*Data format*Analyzed*Experimental factors*Data are analyzed to figure out the outcomes related variables*Experimental features*Retrospective, observational, and nationwide population-based cohort study of patients with non-traumatic cardiac arrest*Data source location*A nationwide cohort study in Taiwan*Data accessibility*The analyzed data is with this article.*

**Value of the data**•The data provide information the ways of coding co-morbidities and hospital levels in the resuscitation study. The short term outcomes of survival to hospital admission, intermediate outcome of survival to hospital discharge are important in cardiac arrest patient.•The data provides the information so that the effects of specific intervention can be comprehensively figured out and compared.•Subgroup analysis of patients with different dosage of epinephrine used in resuscitation show the interaction with effects of anti-arrhythmic agents.

1. Data {#s0005}
=======

The data contains the information of co-morbidities coding from ICD-9 CM codes and specific difference in requirement between medical centers and non-medical centers in resuscitation as shown in [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}. Univariate and multivariate logistic regression analysis for factors related to the outcome of survival to ICU admission and survival to hospital discharge are included in the data set [Table 3a](#t0015){ref-type="table"}, [Table 3b](#t0020){ref-type="table"}. The data also contains bootstrap sensitivity analysis of the logistic regression model for survival to ICU admission and hospital discharge outcomes in out-of-hospital cardiac arrest as shown in [Table 4](#t0025){ref-type="table"}. Subgroup analysis of epinephrine dosage related to outcome of one-year survival is shown in [Table 5](#t0030){ref-type="table"}.

2. Experimental design, materials and methods {#s0010}
=============================================

Medical records/reports accruing between years 2004 and 2011 were retrieved from the Taiwan National Health Insurance Research Database (NHIRD) for review. This repository releases anonymous secondary data for research purposes and houses all claims data from the National Health Insurance (NHI) program in Taiwan. Launched in 1995, the NHI provides coverage for \>99% of the entire Taiwanese population of 23.74 million [@bib2]. The database details all patient demographics and orders for medical care. Taiwan׳s NHI Bureau is responsible for comprehensive review of medical records and examination reports [@bib3]. Disease diagnoses are coded according to the International Classification of Disease, Ninth Revision, Clinical Modification (ICD-9-CM). The study protocol was approved by the National Taiwan University Hospital Research Ethics Committee.

3. Study design {#s0015}
===============

This retrospective, observational, and nationwide population-based cohort study of patients with non-traumatic cardiac arrest was designed to investigate the impact of amiodarone and lidocaine usage on survival outcomes. Subjects were selected entirely from the NHIRD, all undergoing DC shock and cardiopulmonary resuscitation during short emergency room stay between January, 2004 and December, 2011. Grounds for exclusion were stipulated as follows: 1) age \<18 years, 2) trauma-related event, 3) emergency room stay \>6 h, or 4) non-level one triage. Patients were categorized and triaged into level-one if vital signs were extremely unstable and needed immediate resuscitation when presented to emergency department. Any known recipients of lidocaine or amiodarone (oral or intravenous) within 1 year previously were also excluded to minimize therapeutic interference. Patients were followed from cardiac arrest index date to 1-year survival status or death. Analysis was based on data from emergency rooms and hospitalization and not from ambulance or from resuscitation on the scene in the study [@bib1].
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###### 

Co-morbidities coding from ICD-9 CM codes.

Table 1

  Co-morbidities                          ICD-9 CM codes
  --------------------------------------- -----------------------------------------------
  Diabetes mellitus                       250.\*
  Hypertension                            401.\*, 402.\*, 403.\*, 404.\*, 405.\*
  Coronary artery disease                 410.\*, 411.\*, 412.\*, 413.\*, 414.\*
  Congestive heart failure                428.\*
  Atrial fibrillation                     427.31
  Chronic kidney disease                  585
  Malignancy                              140.\*\~172.\*, 174.\*\~194\*, 200.\*\~208.\*
  Chronic obstructive pulmonary disease   491.\*, 492.\*, 494.\*, 496.\*
  Asthma                                  493.\*

###### 

Specific difference in requirement between medical centers and non-medical centers in resuscitation.

Table 2

                                                            Medical centre                                                                                                        Non-medical centre
  --------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------
  Chief of emergency department                             Emergency medicine specialist                                                                                         Any medical specialist
  Physician qualification                                   1.70% of total physicians are fixed in ED2.More than 50% of total fixed physician are emergency medicine specialist   1.30% of total physicians are fixed in ED2.Any medical specialist
  Qualified advanced cardiac life support (ACLS) training   More than 75% of total stuff (including physicians and nurses)                                                        More than 50% of total stuff (including physicians and nurses)
  Management for acute coronary syndrome                    Cardiologist and cardiovascular surgeon consultation at any time                                                      Cardiologist consultation at any time
  Perform percutaneous coronary intervention                1. Always available at any time                                                                                       1. Not always available
                                                            2. Door-to-balloon time \<90 min in 75% of total STEMI patients                                                       2. Transfer the patient if PCI is not available

###### 

Univariate and multivariate logistic regression analysis for factors related to the outcome of survival to ICU admission.

Table 3a

                                                                    Univariate           Multivariate                       
  ----------------------------------------------------------------- -------------------- -------------- ------------------- ----------
  Age (pear year)                                                   0.99(0.99\~0.99)     \<0.0001       0.99 (0.98\~0.99)   \<0.0001
  Male                                                              0.92(0.87\~0.98)     0.0141         0.91(0.85\~0.98)    0.01
  Medication use                                                                                                            
   Both                                                             2.82(2.52\~3.17)     \<0.0001       4.05(3.56\~4.61)    \<0.0001
   Amiodarone                                                       2.04(1.90\~2.18)     \<0.0001       2.23(2.07\~2.41)    \<0.0001
   Lidocaine                                                        1.87(1.62\~2.16)     \<0.0001       2.32(1.99\~2.71)    \<0.0001
   Neither                                                          1                                   1                   
  Urbanization level                                                                                                        
   1                                                                1.35(1.24\~1.47)                    1.23(1.12\~1.36)    \<0.0001
   2                                                                1.41(1.30\~1.52)                    1.26(1.16\~1.37)    \<0.0001
   3                                                                1.22(1.10\~1.37)                    1.36(1.21\~1.53)    \<0.0001
   4                                                                1                                   1                   
  CCI                                                               0.98(0.97\~0.99)     \<0.0001                           
  Pre-existing medical disease[a](#tbl3afna){ref-type="table-fn"}                                                           
   DM                                                               1.06(0.9956\~1.14)   0.06                               
   Hypertension                                                     0.93(0.87\~0.98)     0.01                               
   CAD                                                              0.88(0.82\~0.95)     0.0007         0.89(0.82\~0.97)    0.005
   HF                                                               0.94(0.86\~1.03)     0.18                               
   Af                                                               1.16(0.99\~1.35)     0.06           1.20(1.01\~1.41)    0.03
   CKD                                                              1.16(1.05\~1.28)     0.0024                             
   Malignancy                                                       0.93(0.83\~1.03)     0.17           0.88(0.78\~0.98)    0.02
   COPD                                                             0.80(0.73\~0.88)     \<0.0001                           
   Asthma                                                           0.85(0.75\~0.97)     0.01                               
  Year of events                                                                                                            
   2004                                                             1                                   1                   
   2005                                                             1.17(1.03\~1.33)     0.01           1.19(1.04\~1.35)    0.01
   2006                                                             1.54(1.37\~1.74)     \<0.0001       1.50(1.32\~1.70)    \<0.0001
   2007                                                             1.54(1.36\~1.74)     \<0.0001       1.48(1.30\~1.69)    \<0.0001
   2008                                                             1.82(1.61\~2.05)     \<0.0001       1.75(1.54\~1.99)    \<0.0001
   2009                                                             1.78(1.57\~2.01)     \<0.0001       1.81(1.59\~2.06)    \<0.0001
   2010                                                             1.82(1.61\~2.07)     \<0.0001       1.78(1.56\~2.03)    \<0.0001
   2011                                                             1.73(1.52\~1.96)     \<0.0001       1.72(1.50\~1.97)    \<0.0001
  Epinephrine dose (per mg)                                         0.90(0.89\~0.90)     \<0.0001       0.87(0.87\~0.88)    \<0.0001
  Vasopressin use                                                   2.14(0.97\~4.48)     0.03           2.86(1.35\~6.06)    0.006
  Resuscitation in medical centre                                   1.70(1.58\~1.82)     \<0.0001       1.60(1.47\~1.74)    \<0.0001

Regression to age, gender, underlying diseases, Charlson comorbidity index, epinephrine dose, vasopressin use, hospital level, urbanization level, year of event.

OD: odds ratio, CI: confidence interval.

CCI: Charlson comorbidity index; DM: diabetes mellitus; CAD: coronary artery disease; HF: heart failure; Af: atrial fibrillation; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease.

###### 

Univariate and multivariate analysis for factors related to the outcome of survival to hospital discharge.

Table 3b

                                                                    Univariate            Multivariate                         
  ----------------------------------------------------------------- --------------------- -------------- --------------------- ----------
  Age, pear year                                                    0.98(0.98\~0.98)      \<0.0001       0.99(0.98\~0.99)      \<0.0001
  Male                                                              1.16(1.03\~1.30)      0.01                                 
  Medication                                                                                                                   
   Both                                                             4.46(3.76\~5.28)      \<0.0001       4.26(3.36\~5.41)      \<0.0001
   Amiodarone                                                       3.08(2.74\~3.45)      \<0.0001       2.79(2.40\~3.24)      \<0.0001
   Lidocaine                                                        2.66(2.11\~3.35)      \<0.0001       2.51(1.88\~3.36)      \<0.0001
   Neither                                                          1                                    1                     
  Urbanization Level                                                                                                           
   1                                                                1.50 (1.29\~1.73)     \<0.0001                             
   2                                                                1.35 (1.18\~1.55)     \<0.0001                             
   3                                                                1.13 (0.93\~1.38)     0.23                                 
   4                                                                1                                                          
  CCI                                                               0.88(0.86\~0.90)      \<0.0001       0.95(0.92\~0.99)      0.005
  Pre-existing medical disease[a](#tbl3bfna){ref-type="table-fn"}                                                              
   DM                                                               0.77(0.68\~0.88)      \<0.0001                             
   Hypertension                                                     0.80(0.71\~0.89)      \<0.0001                             
   CAD                                                              0.81(0.71\~0.93)      0.0026                               
   heart failure                                                    0.86(0.73\~1.00)      0.052                                
   Af                                                               0.90(0.66\~1.21)      0.50                                 
   CKD                                                              1.03(0.86\~1.23)      0.74           1.46(1.16\~1.84)      0.001
   Malignancy                                                       0.63(0.50\~0.79)      \<0.0001                             
   CPOD                                                             0.58(0.49\~0.69)      \<0.0001                             
   Asthma                                                           0.76(0.59\~0.97)      0.03           1.45(1.12\~1.90)      0.006
  Year of events                                                                                                               
   2004                                                             1                                                          
   2005                                                             1.13(0.90\~1.42)      0.29                                 
   2006                                                             1.44(1.16\~1.79)      0.0011                               
   2007                                                             1.53(1.23\~1.91)      0.0002                               
   2008                                                             1.78(1.44\~2.21)      \<0.0001                             
   2009                                                             1.85(1.49\~2.30)      \<0.0001                             
   2010                                                             1.86(1.49\~2.32)      \<0.0001                             
   2011                                                             1.73(1.38\~2.17)      \<0.0001                             
  Epinephrine dose (per mg)                                         0.79(0.78\~0.80)      \<0.0001       0.80(0.79\~0.81)      \<0.0001
  Vasopressin                                                       1.04(0.12\~4.07)      0.72                                 
  Resuscitation in medical centre                                   1.91(1.70\~2.14)      \<0.0001       1.38(1.19\~1.61)      \<0.0001
  Coronary angiography                                              66.71(56.90\~78.25)   \<0.0001       32.86(27.11\~39.83)   \<0.0001
  Hypothermia                                                       11.28 (6.92\~18.14)   \<0.0001                             

Regression to age, gender, underlying diseases, Charlson comorbidity index, epinephrine dose, vasopressin use, hospital level, urbanization level, year of event, coronary angiography.

OD: odds ratio, CI: confidence interval.

CCI: Charlson comorbidity index; DM: diabetes mellitus; CAD: coronary artery disease; HF: heart failure; Af: atrial fibrillation; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease.

###### 

Bootstrap sensitivity analysis of the logistic regression model for survival to ICU admission and hospital discharge outcomes in out-of-hospital cardiac arrest.

Table 4

                                                       Survival to ICU admission   Survival to discharge                      
  ---------------------------------------------------- --------------------------- ----------------------- ------------------ ----------
  Primary analysis                                                                                                            
   Both                                                4.05(4.04\~4.07)            \<0.0001                4.17(4.14\~4.20)   \<0.0001
   Amiodarone                                          2.23(2.23\~2.24)            \<0.0001                2.72(2.70\~2.73)   \<0.0001
   Lidocaine                                           2.33(2.32\~2.34)            \<0.0001                2.51(2.48\~2.53)   \<0.0001
   Neither                                             Reference                                           Reference          
                                                                                                                              
  Excluding patients with pre-existing malignancy                                                                             
   Both                                                4.15(4.13\~4.17)            \<0.0001                4.14(4.11\~4.17)   \<0.0001
   Amiodarone                                          2.32(2.31\~2.32)            \<0.0001                2.71(2.70\~2.73)   \<0.0001
   Lidocaine                                           2.51(2.50\~2.52)            \<0.0001                2.63(2.60\~2.65)   \<0.0001
   Neither                                             Reference                                           Reference          
                                                                                                                              
  Excluding patients receiving no epinephrine                                                                                 
   Both                                                3.97(3.95\~3.99)            \<0.0001                4.43(4.39\~4.46)   \<0.0001
   Amiodarone                                          2.16(2.16\~2.17)            \<0.0001                2.81(2.80\~2.83)   \<0.0001
   Lidocaine                                           2.19(2.18\~2.20)            \<0.0001                2.41(2.39\~2.44)   \<0.0001
   Neither                                             Reference                                           Reference          
                                                                                                                              
  Excluding patients receiving epinephrine 0 or 1 mg                                                                          
   Both                                                3.86(3.85\~3.88)            \<0.0001                4.38(4.34\~4.11)   \<0.0001
   Amiodarone                                          2.12(2.11\~2.12)            \<0.0001                2.86(2.84\~2.87)   \<0.0001
   Lidocaine                                           2.11(2.10\~2.12)            \<0.0001                2.46(2.43\~2.49)   \<0.0001
   Neither                                             Reference                                           Reference          

OR: odds ratio, CI: confidence interval.

###### 

Subgroup analysis of epinephrine dosage related to outcome of one-year survival^⁎^.

Table 5

  Epinephrine dosage   Both               Amiodarone         Lidocaine          Neither
  -------------------- ------------------ ------------------ ------------------ -----------
  \<=5 mg              2.60(1.72\~3.93)   2.36(1.88\~2.96)   2.06(1.34\~3.16)   Reference
   P value             \<0.0001           \<0.0001           0.0009             
  6--10 mg             2.47(1.54\~3.98)   2.37(1.79\~3.14)   1.83(1.01\~3.32)   Reference
   P value             0.0002             \<0.0001           0.047              
  11--15 mg            2.51(1.45\~4.33)   1.18(0.78\~1.80)   1.31(0.56\~3.05)   Reference
   P value             0.001              0.43               0.54               
  \>15 mg              1.46(0.85\~2.51)   1.33(0.88\~2.02)   1.18(0.46\~2.98)   Reference
   *P* value           0.17               0.17               0.73               

*P* value for interaction \<0.0001.
